Carregant...
Deferasirox for managing transfusional iron overload in people with sickle cell disease
BACKGROUND: Sickle cell disease (SCD) is a group of genetic haemoglobin disorders, that occurs in about 2.2 per 1000 births worldwide. Increasingly, some people with SCD develop secondary iron overload due to occasional red blood cell transfusions or are on long‐term transfusion programmes for e.g....
Guardat en:
| Publicat a: | Cochrane Database Syst Rev |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Ltd
2014
|
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6489379/ https://ncbi.nlm.nih.gov/pubmed/24893174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD007477.pub3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|